{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bryushkova EA"],"funding":["Ministry of science"],"pagination":["e0273340"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401152"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(8)"],"pubmed_abstract":["Objective
The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (netakimab), anti-IL-6R (tocilizumab), or JAK1/JAK2 inhibitor (baricitinib) or with a standard-of-care therapy alone.Methods
The observational cohort study included 154 adults hospitalized between February and August, 2020 with RT-PCR-confirmed SARS-CoV-2 with National Early Warning Score2 (NEWS2) < 7 and C-reactive protein (CRP) levels ≤ 140 mg/L on the day of the start of the therapy or observation. Patients were divided into the following groups: I) 4 mg baricitinib, 1 or 2 times a day for an average"],"journal":["PloS one"],"pubmed_title":["Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study."],"pmcid":["PMC9401152"],"funding_grant_id":["075-15-2020-807"],"pubmed_authors":["Mutovina ZY","Fomina DS","Lukyanov SA","Kruglova TS","Tkacheva ON","Akopyan AA","Chudakov DM","Bryushkova EA","Zagrebneva AI","Skatova VD","Strazhesko ID","Lysenko MA"],"additional_accession":[]},"is_claimable":false,"name":"Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.","description":"Objective
The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (netakimab), anti-IL-6R (tocilizumab), or JAK1/JAK2 inhibitor (baricitinib) or with a standard-of-care therapy alone.Methods
The observational cohort study included 154 adults hospitalized between February and August, 2020 with RT-PCR-confirmed SARS-CoV-2 with National Early Warning Score2 (NEWS2) < 7 and C-reactive protein (CRP) levels ≤ 140 mg/L on the day of the start of the therapy or observation. Patients were divided into the following groups: I) 4 mg baricitinib, 1 or 2 times a day for an average","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-06-01T02:20:43.823Z","creation":"2025-04-05T15:17:36.165Z"},"accession":"S-EPMC9401152","cross_references":{"pubmed":["36001576"],"doi":["10.1371/journal.pone.0273340"]}}